CN104011054B - 用作钾通道抑制剂的噻吩并和呋喃并嘧啶类和吡啶类 - Google Patents

用作钾通道抑制剂的噻吩并和呋喃并嘧啶类和吡啶类 Download PDF

Info

Publication number
CN104011054B
CN104011054B CN201280061286.3A CN201280061286A CN104011054B CN 104011054 B CN104011054 B CN 104011054B CN 201280061286 A CN201280061286 A CN 201280061286A CN 104011054 B CN104011054 B CN 104011054B
Authority
CN
China
Prior art keywords
alkyl
optionally substituted
piperidinyl
thieno
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280061286.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104011054A (zh
Inventor
戴维·玛奇
费奥纳·尚
德雷克·爱德华·约翰
西蒙·D·爱德华兹
理查德·布伦特
巴兹尔·哈茨奥拉基斯
林赛·布朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sen Shen Co Ltd
Original Assignee
Sen Shen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1119703.5A external-priority patent/GB201119703D0/en
Priority claimed from GBGB1214250.1A external-priority patent/GB201214250D0/en
Application filed by Sen Shen Co Ltd filed Critical Sen Shen Co Ltd
Publication of CN104011054A publication Critical patent/CN104011054A/zh
Application granted granted Critical
Publication of CN104011054B publication Critical patent/CN104011054B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201280061286.3A 2011-11-15 2012-11-15 用作钾通道抑制剂的噻吩并和呋喃并嘧啶类和吡啶类 Expired - Fee Related CN104011054B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1119703.5A GB201119703D0 (en) 2011-11-15 2011-11-15 Compounds
GB1119703.5 2011-11-15
GBGB1214250.1A GB201214250D0 (en) 2012-08-09 2012-08-09 Compounds
GB1214250.1 2012-08-09
PCT/GB2012/052842 WO2013072694A1 (en) 2011-11-15 2012-11-15 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors

Publications (2)

Publication Number Publication Date
CN104011054A CN104011054A (zh) 2014-08-27
CN104011054B true CN104011054B (zh) 2016-08-24

Family

ID=47222145

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280061286.3A Expired - Fee Related CN104011054B (zh) 2011-11-15 2012-11-15 用作钾通道抑制剂的噻吩并和呋喃并嘧啶类和吡啶类

Country Status (15)

Country Link
US (2) US9290511B2 (enExample)
EP (1) EP2780343A1 (enExample)
JP (1) JP2014533259A (enExample)
KR (1) KR20140094603A (enExample)
CN (1) CN104011054B (enExample)
AR (1) AR090037A1 (enExample)
AU (1) AU2012338570A1 (enExample)
BR (1) BR112014011671A2 (enExample)
CA (1) CA2855346A1 (enExample)
IN (1) IN2014MN01183A (enExample)
MX (1) MX2014005935A (enExample)
RU (1) RU2014124101A (enExample)
TW (1) TWI498331B (enExample)
WO (1) WO2013072694A1 (enExample)
ZA (1) ZA201403503B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO3006443T3 (enExample) 2013-06-06 2018-09-22
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU2545758C1 (ru) * 2014-03-20 2015-04-10 Общество с ограниченной ответственностью "Алион" Бициклические пиримидины или их фармацевтически приемлемые соли-активаторы антиоксидантной программы и их применение в качестве цитопротекторов
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US10221191B2 (en) 2015-12-22 2019-03-05 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
CN114539284A (zh) * 2016-03-16 2022-05-27 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
BR112018068702A2 (pt) 2016-03-16 2019-01-15 Kura Oncology Inc inibidores bicíclicos em ponte de menin-mll e métodos de uso
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
WO2018125810A1 (en) 2016-12-28 2018-07-05 Dart Neuroscience, Llc Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
EA038388B1 (ru) * 2017-01-16 2021-08-19 Кура Онколоджи, Инк. Замещенные ингибиторы менина-mll и способы применения
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
SG11201911929XA (en) 2017-06-21 2020-01-30 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
JP7158464B2 (ja) * 2017-08-14 2022-10-21 アセシオン ファーマ エイピーエス カリウムチャネル阻害剤としての置換ベンゾイミダゾール
WO2019060365A1 (en) 2017-09-20 2019-03-28 Kura Oncology, Inc. SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
CN111655695B (zh) 2017-11-27 2025-05-27 达特神经科学有限公司 作为pde1抑制剂的取代的呋喃并嘧啶化合物
CN108117556A (zh) * 2018-01-15 2018-06-05 王山川 一种细胞周期检查点激酶1抑制剂的合成方法
EP3871673B1 (en) 2018-10-26 2024-01-03 Taiho Pharmaceutical Co., Ltd. Novel indazole compound or salt thereof
WO2020132071A1 (en) 2018-12-19 2020-06-25 Shy Therapeutics. Llc Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
TW202039481A (zh) 2018-12-21 2020-11-01 美商西建公司 Ripk2之噻吩并吡啶抑制劑
CA3158793A1 (en) 2019-10-28 2021-05-06 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2022194191A1 (en) * 2021-03-16 2022-09-22 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of kras g12d
JP2024511101A (ja) * 2021-03-22 2024-03-12 アセシオン ファーマ エイピーエス 新規カリウムチャネル阻害剤
WO2022204720A1 (en) * 2021-03-26 2022-09-29 Sumitomo Pharma Oncology, Inc. (furopyrimidin-4-yl)piperazine compounds and uses thereof
CN115006468B (zh) * 2022-06-28 2023-06-06 西安外事学院 一种复方中草药生发液及制备方法
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065391A1 (en) * 2003-01-23 2004-08-05 Almirall Prodesfarma S.A. 4-AMINOTHIENO[2,3-d]PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS
WO2006061642A1 (en) * 2004-12-09 2006-06-15 Xention Discovery Limited Compounds
CN1823071A (zh) * 2003-06-11 2006-08-23 润生开发有限公司 用作钾通道抑制剂的噻吩并嘧啶衍生物
WO2007066127A2 (en) * 2005-12-09 2007-06-14 Xention Limited Thieno ( 3 , 2-c) pyridine compounds

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
BR9101256A (pt) * 1990-03-30 1991-11-05 Dowelanco Composto,composicao fungicida,processo fungicida,composicao inseticida ou acaricida e processo inseticida ou acaricida
JP2001500482A (ja) 1996-08-27 2001-01-16 ノバルティス アクチェンゲゼルシャフト 除草性ｓ置換１，２，４，６―チアトリアジン類
WO2004011057A1 (en) 1998-02-07 2004-02-05 Advanced Cardiovascular Systems, Inc. Perfusion dilatation catherer with expanded support coil
JP2001097979A (ja) 1999-07-28 2001-04-10 Takeda Chem Ind Ltd 縮合複素環化合物、その製造法および用途
WO2001021610A1 (en) 1999-09-17 2001-03-29 Nissan Chemical Industries, Ltd. Benzopyran derivative
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
SE9904738D0 (sv) 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
DE10031585A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 2-Aminoalkyl-thieno[2,3-d]pyrimidine
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
ATE305930T1 (de) 2001-06-25 2005-10-15 Nissan Chemical Ind Ltd Substituierte benzopyran derivate gegen arrhythmie
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
JP2005508904A (ja) * 2001-09-11 2005-04-07 スミスクライン ビーチャム コーポレーション 血管新生阻害剤としてのフロ−及びチエノピリミジン誘導体
US20040138238A1 (en) * 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
GB0315950D0 (en) * 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
US7594219B2 (en) 2003-07-24 2009-09-22 International Business Machines Corporation Method and apparatus for monitoring compatibility of software combinations
TWI346112B (en) 2004-02-25 2011-08-01 Nissan Chemical Ind Ltd Benzopyran compound
BRPI0509795A (pt) * 2004-04-12 2007-10-23 Sankyo Co composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso do composto ou sal farmacologicamente aceitável do mesmo, e, método para promover osteogênese, supressão de ressorção óssea e/ou melhoramento da densidade óssea
EP1758909A1 (en) 2004-06-10 2007-03-07 Xention Limited Furanopyrimidine compounds effective as potassium channel inhibitors
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
KR20140008471A (ko) 2004-10-21 2014-01-21 다우 아그로사이언시즈 엘엘씨 살진균 활성을 갖는 티에노-피리미딘 화합물
US7576212B2 (en) * 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
US7576080B2 (en) 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
EP1844052A1 (en) 2005-01-26 2007-10-17 Pharmacia & Upjohn Company LLC Thieno[2,3-d]pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
JP2008534488A (ja) 2005-03-25 2008-08-28 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 血小板凝集阻害剤としての４−ピペラジニルチエノ［２，３−ｄ］ピリミジン化合物
JP2008534573A (ja) 2005-03-28 2008-08-28 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 血小板凝集阻害剤としての４−ピペラジノチエノ［２，３−ｄ］ピリミジン化合物
WO2006103545A1 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors
CA2603041A1 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
US20060281768A1 (en) * 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
AU2006261082B2 (en) * 2005-06-22 2012-04-19 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
ATE455117T1 (de) * 2005-09-23 2010-01-15 Equispharm Co Ltd 5,6-dimethylthienoä2,3-diüpyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung für die bekämpfung von viren
WO2007056214A2 (en) * 2005-11-02 2007-05-18 Cytovia, Inc N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof
WO2007115822A1 (en) * 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnkl /mnk2 inhibiting activity for pharmaceutical compositions
MX2008015908A (es) 2006-06-12 2009-01-28 Vertex Pharma Tienopirimidinas utiles como moduladores de canales de iones.
DE102006030236A1 (de) 2006-06-30 2008-01-03 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Direktoxidationsbrennstoffzelle für den konvektionsfreien Transport des Brennstoffs und Verfahren zum Betreiben der Brennstoffzelle
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
GB0713602D0 (en) 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
BRPI0816922A2 (pt) * 2007-09-14 2015-03-17 Janssen Pharmaceutica Nv Moduladores tieno e furo-pirimidina do receptor de histamina h4
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
MY156226A (en) 2008-02-22 2016-01-29 Otsuka Pharma Co Ltd Benzodiazepine compound and pharmaceutical composition
US20100227853A1 (en) 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
CN102186857A (zh) * 2008-08-26 2011-09-14 贝林格尔·英格海姆国际有限公司 用于药物组合物的噻吩并嘧啶
TWI334124B (en) * 2008-08-28 2010-12-01 Au Optronics Corp Display drive circuit for flat panel display and driving method for gate lines
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
AU2009291783A1 (en) 2008-09-10 2010-03-18 Alcon Research, Ltd Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
WO2010033127A1 (en) 2008-09-22 2010-03-25 Sionyx, Inc. Response-enhanced monolithic-hybrid pixel
WO2011029054A1 (en) 2009-09-04 2011-03-10 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
CN102791718B (zh) 2009-10-29 2015-11-25 百时美施贵宝公司 作为α-7烟碱乙酰胆碱受体配体的奎宁环化合物
EP2519519A4 (en) 2009-12-30 2013-04-24 Arqule Inc Substituted Naphthalenyl-pyrimidine compounds
TW201219401A (en) * 2010-09-14 2012-05-16 Lexicon Pharmaceuticals Inc Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
US8703941B2 (en) 2011-01-10 2014-04-22 Nimbus Iris, Inc. IRAK inhibitors and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065391A1 (en) * 2003-01-23 2004-08-05 Almirall Prodesfarma S.A. 4-AMINOTHIENO[2,3-d]PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS
CN1823071A (zh) * 2003-06-11 2006-08-23 润生开发有限公司 用作钾通道抑制剂的噻吩并嘧啶衍生物
WO2006061642A1 (en) * 2004-12-09 2006-06-15 Xention Discovery Limited Compounds
WO2007066127A2 (en) * 2005-12-09 2007-06-14 Xention Limited Thieno ( 3 , 2-c) pyridine compounds

Also Published As

Publication number Publication date
ZA201403503B (en) 2016-09-28
CA2855346A1 (en) 2013-05-23
TW201326178A (zh) 2013-07-01
US20160152634A1 (en) 2016-06-02
WO2013072694A1 (en) 2013-05-23
US9290511B2 (en) 2016-03-22
EP2780343A1 (en) 2014-09-24
JP2014533259A (ja) 2014-12-11
RU2014124101A (ru) 2015-12-27
US20140371203A1 (en) 2014-12-18
AU2012338570A1 (en) 2014-07-03
BR112014011671A2 (pt) 2017-05-30
NZ626199A (en) 2015-04-24
CN104011054A (zh) 2014-08-27
AR090037A1 (es) 2014-10-15
KR20140094603A (ko) 2014-07-30
MX2014005935A (es) 2014-09-04
IN2014MN01183A (enExample) 2015-07-03
TWI498331B (zh) 2015-09-01

Similar Documents

Publication Publication Date Title
CN104011054B (zh) 用作钾通道抑制剂的噻吩并和呋喃并嘧啶类和吡啶类
TWI869519B (zh) Sos1抑制劑
AU2002338334B2 (en) N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists
IL282622A (en) Substituted tricyclic compounds as fgfr inhibitors
WO2023066350A1 (zh) Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用
KR102517352B1 (ko) Nik 억제제로서의 헤테로방향족 유도체
US11180487B2 (en) Substituted cyanoindoline derivatives as NIK inhibitors
CN104755083B (zh) 氨基烷基哌嗪的脲和酰胺衍生物及其用途
CN103781776A (zh) 用作端锚聚合酶抑制剂的新的2-哌啶-1-基-乙酰胺化合物
WO2016116025A1 (zh) Jak抑制剂
JP2013501002A (ja) Ｓｙｋキナーゼ阻害剤としての化合物および組成物
MX2012009208A (es) Compuestos de 8-metil-1-fenil-imidazol[1, 5-a]pirazina.
JP7716777B2 (ja) 窒素含有多環式縮合環系化合物、その医薬組成物、製造方法及び用途
KR20160086404A (ko) Mknk1 및 mknk2 억제제로서의 티에노피리미딘
TWI869674B (zh) 雜芳基衍生化合物及其用途
TW202517653A (zh) 治療自體免疫疾病之大環
JP2014533258A (ja) カリウムチャネル阻害剤としてのチエノ［２，３−ｃ］ピラゾールの使用
NZ626199B2 (en) Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors
CN117466893A (zh) 吡啶并环庚烷类衍生物及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160824

Termination date: 20161115